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Abstract
Background: Management of patients with the brugada ECG sign who have no previous history of syncope is still negotiable. We present 
a case of a 57 year-old Caucasian lady who presented to the emergency department with substernal chest pain. Results: Her past medical 
history showed that she had two previous episodes of lightheadedness, but no syncope. She had a family history of sudden death secon-
dary to unknown cause in her aunt at the age of 61. Physical exam was unremarkable except for diaphoresis. Electrocardiography (ECG) 
showed ST elevation in the right precordial leads (V1-V2) with T inversion, mimicking a STEMI. Emergent cardiac catheterization revealed 
normal coronary arteries. Echocardiogram was normal. Again, interpretation of ECG revealed a Brugada type 1 pattern, characterized by 
coved-type, gradually descending ST-T segment, elevated J point of more than 2 mm and T wave inversion. Electrophysiological (EPS) 
testing with a Sodium channel blocker challenge showed a persistent Brugada type 1 pattern with non-inducible ventricular tachycardia. 
This patient had Brugada type 1 ECG pattern with no previous history of syncope (asymptomatic). Thus she was considered at low risk 
of developing a serious arrhythmogenic event in the future. Conclusion: A history of syncope remains the best available predictor for 
arrhythmogenic events. EPS testing in such patients, to stratify the risk and predict for any future events, is still controversial. It is still 
unjustified to place an implantable cardioverter-defibrillator in asymptomatic non-inducible individuals with the Brugada pattern. These 
patients should follow up closely with a cardiologist and be aware of the risk of possible triggers of ventricular arrhythmias.
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Introduction
The Brugada pattern is characterized by ECG changes alone, 
without any of the clinical features of Brugada Syndrome. 
The ECG changes can be one of three types and can be 
dynamic. However, the patient should have the type 1 ECG 
pattern “coved-type” to make the diagnosis of Brugada. 
The following case report and discussion focuses on the 
presentation, diagnosis, management and prognosis of the 
asymptomatic patient with a Brugada ECG pattern.
The Case
A 57-year-old Caucasian lady presented to the emergency 
department (ED) with substernal chest pain of one day du-
ration. It was associated with headache, backache and mild 
dyspnea. She reported 2 episodes of lightheadedness in 
the past month when she felt she was about to pass out. 
The episodes lasted for a few seconds and were relieved 
spontaneously. She denied syncope, dizziness, cough, pal-
pitations, nausea or vomiting.
Her past medical history included hypertension, migraine, 
depression, attention deficit hyperactivity disorder, chronic 
sinusitis and asthma. Her home medications included 
lisinopril, gabapentin, trazodone, adderall, celebrex and 
flovent diskus. She has history of allergy to codeine sulfate. 
Her family history included hypertension and coronary 
artery disease, however it was significant for sudden death 
of unknown cause in her aunt at the age of 61. She also 
had a 48-pack-year history of smoking, but quit 7 years ago. 
She used to work as a hairstylist and consumed alcohol 
occasionally.
On physical examination, the patient was diaphoretic and 
in moderate distress in the ED. The ECG was interpreted 
by the on-call ER physician as a STEMI (Figure 1) and 
the cardiac catheterization team was activated. Coronary 
angiography revealed normal coronary arteries. Laboratory 
results revealed hypokalemia K = 2.9, and otherwise normal 
CBC, cardiac enzymes and other electrolytes. Transthoracic 
echocardiography showed a normal left ventricular ejection 
fraction and no structural heart disease. 
Submission: May 4, 2012. 




Omar Mousa is an Internal 
Medicine resident at State 
University of New York – 
Upstate Medical University, 
Syracuse, NY, USA
The International Journal of Medical Students 87www.ijms.info   •   2013  |  Vol 1  |  Issue 2  
Case Report
Figure 1. Electrocardiography of 57 years-old lady showing a Brugada type 1 pattern, characterized by the coved-type, gradually descending ST-T segment 
elevation, J wave and T inversion in leads V1-V2 and incomplete RBBB in the emergency department.
Figure 2. Electrocardiography of the same lady showed a persistent Brugada type 1 ECG pattern on the 5th day of admission. The patient was afebrile and 
recovering from a community acquired pneumonia on antibiotics.
The electrophysiology service was consulted and 
reevaluation of the ECG revealed coved-type J point and 
ST elevation in the right precordial leads (V1-V2) with 
incomplete right bundle branch block (RBBB), illustrating 
Brugada type 1 pattern. Cardiac MRI study showed no 
evidence of arrhythmogenic right ventricular dysplasia 
(ARVD). Genetic testing for SCN5A mutation wasn’t 
performed.
The patient was transferred to telemetry for observation. 
Electrophysiological study (EPS) was planned for the next 
day due to a Brugada type 1 pattern on ECG with non-
sustained ventricular tachycardia, when the patient was 
found to have fever (101.2 F), tachycardia, shortness of 
breath and cough. 
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Physical examination and chest X-ray showed left lower 
lobe infiltrate with left pleural effusion. Labs showed 
leukopenia and a positive urine test for the Streptococcus 
pneumonia antigen. She was diagnosed with community 
acquired pneumonia and antibiotics were started.
On the 6th day of admission, the patient was doing well and 
afebrile. A persistent Brugada type 1 ECG pattern is shown 
in (Figure 2). EPS was performed with provocative testing 
using procainamide. It revealed Brugada type 1 ECG pattern 
but no VT was induced with up to triple ventricular extra 
stimuli from right ventricular apex and base, on and off 
isuprel. The patient was asymptomatic and no implantable 
cardioverter defibrillator (ICD) was implanted. She was 
discharged home and scheduled to follow up closely with 
her cardiologist. 
Discussion   
Sudden cardiac death (SCD) in patients with normal hearts 
is an uncommon occurrence.1 Brugada syndrome (BrS) 
was described in 1992 as one of the causes of SCD in 
patients with normal heart structure.2,3 This syndrome of 
high incidence of life-threatening ventricular arrhythmias 
is associated with ECG changes consistent with ST segment 
elevation in leads V1 to V3 and incomplete right bundle 
branch block.2,4-6 Due to the availability of a preventable 
mode of therapy, an implantable cardioverter-defibrillator 
(ICD) should be considered when definitive diagnosis of 
BrS is made.7
The Brugada pattern is characterized solely by the typical 
Brugada ECG changes, excluding the following clinical 
features: documented ventricular fibrillation (VF), self-
terminating polymorphic ventricular tachycardia (VT), 
family history of SCD at the age <45 years, type 1 ST segment 
elevation in family members, electrophysiologic inducibility 
of VT, unexplained syncope suggestive of tachyarrhythmia 
or nocturnal agonal respiration. The Brugada ECG pattern 
has a coved-type, gradually descending ST-T segment, J 
wave amplitude of more than 2mm and T wave inversion.8,9 
Characteristics of patients with the Brugada ECG pattern 
included higher prevalence in the Asian population.6 
However, the exact prevalence varied among studies from 
different countries.13,14,18-21 It was mainly observed in adult 
males19,22 and a mutation in SCN5A gene on chromosome 
3p21-24, that codes for the alpha-subunit of cardiac sodium 
channels, was found in about 18-30% of families with 
BrS.11,15,23,24
The relation between the Brugada ECG sign in asymptomatic 
patients (no previous history of syncope) and the future risk 
of developing arrhythmogenic events has been investigated, 
especially over the past decade. One study revealed that 
the cardiac event rate per year in asymptomatic patients 
was 0.5%, compared to 1.9% in patients with a history of 
syncope and 7.7% in patients with aborted SCD.10 Further 
reports of extended follow up of the asymptomatic 
population over a period of 3 to 7 years showed none to 
a very low arrhythmogenic event rate.4,9,11-15 Variations in 
the baseline characteristics of asymptomatic patients over 
a mean follow up of 2 to 3 years, revealed different rates of 
arrhythmias, with events arising in 8% of the asymptomatic 
population studied by Brugada et al,16,17 compared to 0.8% 
in a later study by Eckardt et al.17 
Multiple predictors of future arrhythmic events in patients 
with the Brugada pattern were studied, with male gender, 
mutation of the SCN5A gene and a positive family history 
of SCD found to be non-predictive.10,16,30 The prognostic 
value of the clinical, ECG and EPS variables was analyzed 
in a population of spontaneous type 1 Brugada ECG 
patterns and no previous cardiac arrest. The cohort with 
negative EPS (non-inducibility of VT/VF) had a 1.8% risk 
of developing arrhythmic events (SCD or documented VF), 
compared to 14% in those with a positive EPS.30 Further 
studies revealed a 0.9% rate of significant cardiac events 
in patients with non-inducible arrhythmias.16,31 A recent 
prospective multicenter study showed that a positive EPS is 
not predictive for arrhythmic events, and data reported that 
the spontaneous ECG pattern and the history of syncope 
are the best available predictors of such events.10,32 It also 
showed that QRS fragmentation and a ventricular effective 
refractory period of less than 200ms are risk indicators. 
These findings are imperative indicators for the need of an 
implantable cardioverter defibrillator in such populations.32 
Additional literature review revealed the low significance 
of EPS in stratifying the risk of future arrhythmic events, 
and that its role remains an area of investigation and 
debate.9,11,15-17,26,33-39
Currently, pharmacological therapy for the prevention of 
SCD in Brugada patients is not well established, however 
some reports showed that quinidine and hydroquinidine 
may be beneficial in such patients.40-43 The ICD has 
multiple complications, including the relatively high rate 
of inappropriate shocks (6-9% per year), thus it seems to 
be unjustified to give an ICD to the asymptomatic non-
inducible individual with an abnormal ECG pattern.16,23,44-46 
There is no definite evidence to suggest that individuals 
who have no personal history of syncope or any family 
history of SCD are at a higher risk of SCD than the general 
population.4,9,11-13,15
In our case, genetic testing was deferred as only a small 
percentage of patients with the BrS do test positive for 
the SCN5A gene mutation,9,11 and recent reports showed 
that it will not guide the management of such cases.25 We 
excluded other important causes of SCD, including ARVD, 
where the Brugada ECG pattern can be an early subclinical 
manifestation of this genetic disorder.26 Moreover, our 
patient was afebrile on presentation and didn’t have any 
of the known provoking factors that induce a Brugada-like 
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ECG pattern.27,28,29 There was no previous history of syncope 
along with non-inducible VT on provocative EPS testing. 
Lack of such possible predictive factors reflects a low risk of 
developing arrhythmic events and SCD.30 Thus ICD therapy 
wasn’t recommended in this lady as the weight of evidence 
didn’t support it.7 To conclude, our patient was advised to 
follow up carefully with the cardiologist and to be aware 
of the risks of possible triggers of ventricular arrhythmias.
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